Hello from Stuart Roberts in Sydney,
I've very pleased to announce that we've just initiated coverage on ResApp Health (ASX: RAP), a Perth-based company developing a smartphone-based diagnostic for respiratory disease. ResApp's technology, originally developed at the University of Queensland, can detect, through the measurement of coughs and breathing sounds, a range of respiratory disorders including pneumonia, asthma, and COPD with sensitivities and specificities greater than 90% and improving all the time thanks to machine learning. The technology works on existing smartphones with no extra specialised hardware required, making rapid deployment post-regulatory approval a relatively straightforward and highly scalable proposition. ResApp Health is now preparing for a registration study of the technology, ahead of a filing for FDA approval expected in early 2017.
You can download a copy of NDF Research's first report on ResApp Health by clicking here or visiting ndfresearch.com